Liquid Biopsy Cancer Screening (LucenceINSIGHT & SPOT-MAS)

Advanced multi-cancer early detection via liquid biopsy blood tests — SPOT-MAS 10 screens ten cancer types at SGD 785, while LucenceINSIGHT packages screen up to 50 cancer types using next-generation sequencing of circulating tumour DNA, with 80.9% sensitivity and 99% specificity.

Wonderhealth Screeners offers two complementary liquid biopsy platforms for multi-cancer early detection (MCED), both using next-generation sequencing to analyse circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream — enabling detection of cancer signals years before symptoms appear. The SPOT-MAS 10 test (SGD 785, GST-inclusive) screens for ten of the most prevalent cancers in Singapore and Southeast Asia: lung (small cell and non-small cell), colorectal, stomach, liver and biliary tract, head and neck, oesophagus, pancreas, breast, ovary, and uterus. Clinical validation across more than 11,000 participants demonstrated 78.1% sensitivity, 99.8% specificity, and 84% accuracy in identifying the tissue of origin — enabling guided follow-up if a signal is detected. A single 10ml blood draw is processed at a Singapore genomics laboratory, with results available within 12–18 working days. The LucenceINSIGHT platform offers a tiered range of packages based on the number of cancer types screened. The entry-level LucenceINSIGHT 5 (SGD 950) covers five major cancers, while gender-specific packages — Women's 7 (SGD 1,250), Women's 12 (SGD 1,935), and Men's 12 (SGD 1,935) — target the most relevant cancer types for each demographic. The flagship LucenceINSIGHT 50 (SGD 3,650) screens for up to 50 distinct cancer types in a single blood draw, achieving 80.9% overall sensitivity and 99% specificity across its full panel. This makes it one of the broadest cancer screening tools commercially available in Singapore, and particularly valuable for individuals with a strong family history, those seeking maximum peace of mind, or those undergoing regular surveillance. Both tests complement — rather than replace — standard cancer screening programmes such as mammography, colonoscopy, and cervical smears. Results are reviewed with a doctor at Wonderhealth to explain any signals detected and to recommend appropriate imaging or specialist follow-up.